BPH was more remarkable in control group than in case group, 94.8% versus 79.0% (p < 0.001), as selection for control group was largely from BPH patients with clinically apparent LUTS, as well as patients with incidentally determined PSA elevation. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.